ODEPHARMA
ActiveODEPHARMA has been active since 1990 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €116k and a net result of €70k. Equity is growing by ~53.8% per year across the filed fiscal years. Its solvency ranks better than 59% of 10206 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.4% (very low).
Checked score
Score 2025
89
/ 100
Excellent▲ +36 vs 2024
The score combines four axes. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability100▲+8
Solvency87▲+57
Growth78=
Stability100
Bankruptcy probability, 12 months
0.4%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €10k at 30 days acceptable
Liquidity ample (current ratio 1.84 against 1.23 in 2024), but 54.7% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Seven signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Sector 47
higher
← fewer bankruptcies
more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
45.3%
Return on assets
27.3%
Age of the figures
11 mo
neutral · Latest accounts filed on time
The financial year that closed on 30-09-2025 was due by 30-04-2026 and was filed on 03-02-2026, 86 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
86 d early
2024
34 d early
2023
8 d early
2022
2 d early
2021
2 d early
2020
on the day
2019
8 d early
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 30-09-2026 and is due by 30-04-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
12-09-2026 today30-09-2026 close30-04-2027 deadline
Financials · fiscal year 2025, abbreviated schema
Equity
€116k▲ 151%
2024 · €46k
2018: €-74k
2019: €-52k
2020: €-36k
2021: €6k
2022: €16k
2023: €38k
2024: €46k
2018 → 2025
Total assets
€255k▲ 12.3%
2024 · €227k
2018: €266k
2019: €223k
2020: €206k
2021: €223k
2022: €199k
2023: €215k
2024: €227k
2018 → 2025
Net result
€70k▲ 725%
2024 · €8k
2018: €6k
2019: €22k
2020: €17k
2021: €41k
2022: €10k
2023: €21k
2024: €8k
2018 → 2025
Working capital
€114k▲ 172%
2024 · €42k
2018: €-8k
2019: €17k
2020: €25k
2021: €139k
2022: €98k
2023: €121k
2024: €42k
2018 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€6k-€16k▲ 187%€38k▲ 133%€46k▲ 22.5%€116k▲ 151%
Operating result€39k-€9k▼ 77.7%€20k▲ 125%€11k▼ 44.4%€87k▲ 693%
Net result€41k-€10k▼ 74.5%€21k▲ 104%€8k▼ 60.6%€70k▲ 725%
Turnover and EBIT margin not published: the abbreviated schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result recovers in 2025; 2025 is 693% above 2024 and is the highest year so far.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €255k
Fixed assets
€4k▼ 19.1%
Current assets
€251k▲ 13.1%
Equity and liabilities €255k
Equity
€116k▲ 151%
Debt
€140k▼ 22.9%
The debt ratio falls from 79.8% to 54.7%: equity grows while debt is paid down.
Key figures and ratios
EBITDA
€88k▲
2024 · €12k
Cash flow
€71k▲
2024 · €9k
Solvency
45.3%▲
2024 · 20.2%
Current ratio
1.84▲
2024 · 1.23
Quick ratio
0.91▲
2024 · 0.54
Debt / equity
1.21▼
2024 · 3.94
ROE
60.2%▲
2024 · 18.4%
ROA
27.3%▲
2024 · 3.7%
Interest coverage
85.53▲
2024 · 2.72
Debt
€140k▼
2024 · €181k
Debt ≤ 1 year
€137k▼
2024 · €180k
Income taxes
€18k▲
2024 · €2
Staff costs
€134k▲
2024 · €129k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€227k€255k▲
Fixed assets21/28€5k€4k▼
Tangible fixed assets22/27€3k€2k▼
Plant, machinery and equipment23€760€390▼
Furniture and vehicles24€980€516▼
Other tangible fixed assets26€1k€1k▼
Financial fixed assets28€2k€2k=
Current assets29/58€222k€251k▲
Stocks and contracts in progress3€126k€126k▲
Stocks30/36€126k€126k▲
Amounts receivable within one year40/41€69k€64k▼
Trade receivables40€58k€63k▲
Other amounts receivable41€11k€233▼
Cash at bank and in hand54/58€16k€58k▲
Deferred charges and accrued income490/1€11k€3k▼
Equity and liabilities
Total equity and liabilities10/49€227k€255k▲
Equity10/15€46k€116k▲
Contributions10/11€62k€62k=
Capital10€62k€62k=
Issued capital100€62k€62k=
Reserves13€7k€54k▲
Non-distributable reserves130/1€7k€7k=
Legal reserve130€7k€7k=
Distributable reserves133-€47k
Profit (loss) carried forward14€-23k€121▲
Amounts payable17/49€181k€140k▼
Amounts payable after more than one year17€0-
Other amounts payable178/9€0-
Amounts payable within one year42/48€180k€137k▼
Current portion of amounts payable after more than one year42€88k€0▼
Trade debts44€68k€42k▼
Suppliers440/4€68k€42k▼
Taxes, remuneration and social security45€17k€26k▲
Taxes450/3€0€4k▲
Remuneration and social security454/9€17k€22k▲
Other amounts payable47/48€6k€68k▲
Accrued charges and deferred income492/3€2k€3k▲
Income statement
Code20242025
Remuneration, social security and pensions62€129k€134k▲
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€991€1k▲
Other operating charges640/8€923€1k▲
Non-recurring operating charges66A€100€0▼
Gross operating margin9900€142k€223k▲
Operating profit (loss)9901€11k€87k▲
Financial income75/76B€2k€2k▼
Recurring financial income75€2k€2k▼
Financial charges65/66B€4k€1k▼
Recurring financial charges65€4k€1k▼
Profit (loss) for the period before taxes9903€8k€88k▲
Income taxes67/77€2€18k▲
Profit (loss) for the period9904€8k€70k▲
Profit (loss) for the period to be appropriated9905€8k€70k▲
Appropriation of the result
Profit (loss) to be appropriated9906€-23k€47k▲
Profit (loss) brought forward from the previous period14P€-31k€-23k▲
Transfer to equity691/2-€47k
To other reserves6921-€47k
Social balance
Average headcount (FTE)90871.81.9▲
The notes to these accounts (12 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
03-02
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema
2025
30-09
Financial
Highest result since 2018net €70k ▲725%
Operating result €87k, net result €70k, both a record.
30-09
Financial
Equity above €100kEq €116k ▲151%
8 profitable years in a row build equity to €116k.
27-03
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema
2024
22-04
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema
2023
28-04
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema
2022
28-04
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema
2021
30-09
Financial
Liquidity doublescurrent ratio 2.81
Current ratio from 1.14 to 2.81; short-term debt falls from €172k to €76k.
30-04
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema
2020
22-04
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema
2019
30-04
NBB filing
Annual accounts filed
fiscal year 2018 · abbreviated schema
2018
10-04
NBB filing
Annual accounts filed
fiscal year 2017 · abbreviated schema
2017
07-04
NBB filing
Annual accounts filed
fiscal year 2016 · abbreviated schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
3 directors, no change since 2024
LINDAMMER CommV
CurrentDirector · since 01-10-2024 · Legal entity
22-10-2024
LINDAMMER CommV: Appointed as Permanent representative
22-10-2024
PAN PROJECT CV: Resigned as Permanent representative
01-10-2024
LINDAMMER CommV: Appointed as Director
01-10-2024
An LOUWAGIE: Resigned as Director
01-10-2024
Kristiaan TRYPSTEEN: Resigned as Director
01-10-2024
Kristiaan TRYPSTEEN: Resigned as Daily management
Location & real-estate footprint
Registered office, Koksijde · 1 establishment unit since 1990
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Leopold II Laan(Odk) 1688670 KoksijdeGround area
275 m²
Building footprint
106 m²
Volume, LiDAR
1,050 m³
Parcel 38502G0515/00_000, Flanders · tallest building 13.1 m, ±3 floors. Linked by address, not a title deed.
1 establishment unit
APOTHEEK PHARMACIE
since 19902.049.732.239
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 38502G0515/00_000 | Flanders | 275 m² | 1 · 106 m² | 13.1 m · 3 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
APOTHEEK GILIAS
BE 0429.191.940
Oud-Heverlee · Eq €116k
D5-PHARMA
BE 0479.659.456
Ganshoren · Eq €115k
PHARMACIE BEULS
BE 0432.602.380
Mouscron · Eq €116k
CLAIVER
BE 0863.396.307
Heuvelland · Eq €115k
APOTHEEK NAESSENS-CLEEREN
BE 0767.806.369
Schilde · Eq €116k
Of 5,208 companies in sector 47730 we hold annual accounts for 3,850. 3,474 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPublic limited company
Founded12-09-1990
Fiscal year end30-09
Activities, NACEBEL
47730Retail sale of pharmaceutical products
52310
Sources
Crossroads Bank for EnterprisesNational Bank · 35 filingsAddress and cadastre registers
Data from official sources, last processed on 12-09-2026. Scores and ratios are computed by Checked and are not a credit decision.